FDA SRP
The Safety Reporting Portal. The Safety Reporting Portal (SRP) streamlines the process of reporting product safety issues to the Food & Drug Administration (FDA) ... ,2024年4月1日 — To submit via SRP, you must first establish an SRP account. A Gateway partner (i.e., a company that submits ICSRs electronically via the ESG) ... ,2022年9月6日 — • SRP portal features allows for browsing, selecting, and attaching documents to an ICSR. – Follow instructions in SRP to submit attachments ... ,2023年3月20日 — SRP-9001 是用於治療杜氏肌肉萎縮症(Duchenne muscular dystrophy,DMD)的研究型基因療法,這是一種罕見的神經肌肉疾病,由於X 染色體上DMD基因異常,某 ... ,2024年2月16日 — The FDA has accepted Sarepta Therapeutics' efficacy supplement for gene therapy SRP-9001, granting it a priority review for the treatment of ... ,由 DM Rind 著作 · 被引用 2 次 — After FDA leadership strongly encouraged flexibility, the FDA granted SRP-9001 accelerated approval in June 2023 (under the brand name ... ,2024年6月20日 — Elevidy's original approval in 2023 was based upon data from the phase 1/2 SRP-9001-101 (NCT03375164) study, the phase 2 SRP-9001-102 study, and ... ,ELEVIDYS has been evaluated in four clinical studies: SRP-9001-101, SRP-9001-102, SRP-9001-103 (ENDEAVOR) and SRP-9001-301 (EMBARK). Accelerated approval of ... ,2023年3月20日 — 不過事實是,FDA 宣布將在5 月29 日決定藥症是否給予的日期之前召開SRP-9001研究基因治療諮詢委員會會議。這代表有沒有安全問題,還沒有一個定數,這也 ... ,2023年11月27日 — This guidance describes a standards recognition program for regenerative medicine therapies (SRP-RMT) at FDA's Center for Biologics ...
相關軟體 Ares 資訊 | |
---|---|
Ares(原名 Ares Galaxy)是一個免費的開源聊天程序,使用戶能夠共享包括圖像,音頻,視頻,軟件,文檔等在內的任何數字文件。現在,您可以輕鬆地通過 Ares 對等網絡。作為虛擬社區的成員,您可以搜索和下載其他用戶共享的任何文件。最新版本也支持互聯網廣播電台。隨著 Ares 你可以加入聊天室或主辦你的頻道,結識新朋友.Ares 特點:快速多源下載 Ares 自動發現更多的來源和一次下載許多... Ares 軟體介紹
FDA SRP 相關參考資料
Safety Reporting Portal
The Safety Reporting Portal. The Safety Reporting Portal (SRP) streamlines the process of reporting product safety issues to the Food & Drug Administration (FDA) ... https://www.safetyreporting.hh FDA Adverse Event Reporting System (FAERS) Electronic ...
2024年4月1日 — To submit via SRP, you must first establish an SRP account. A Gateway partner (i.e., a company that submits ICSRs electronically via the ESG) ... https://www.fda.gov Safety Reporting Portal (SRP) Registration and Adverse ...
2022年9月6日 — • SRP portal features allows for browsing, selecting, and attaching documents to an ICSR. – Follow instructions in SRP to submit attachments ... https://www.fda.gov 核准前踩剎車!FDA 針對杜氏肌肉萎縮症首支基因轉移療法 ...
2023年3月20日 — SRP-9001 是用於治療杜氏肌肉萎縮症(Duchenne muscular dystrophy,DMD)的研究型基因療法,這是一種罕見的神經肌肉疾病,由於X 染色體上DMD基因異常,某 ... https://geneonline.news FDA Grants Priority Review to Efficacy Supplement for ...
2024年2月16日 — The FDA has accepted Sarepta Therapeutics' efficacy supplement for gene therapy SRP-9001, granting it a priority review for the treatment of ... https://www.neurologylive.com The FDA and Gene Therapy for Duchenne Muscular ...
由 DM Rind 著作 · 被引用 2 次 — After FDA leadership strongly encouraged flexibility, the FDA granted SRP-9001 accelerated approval in June 2023 (under the brand name ... https://jamanetwork.com FDA Approves Sarepta's DMD Gene Therapy Elevidys for ...
2024年6月20日 — Elevidy's original approval in 2023 was based upon data from the phase 1/2 SRP-9001-101 (NCT03375164) study, the phase 2 SRP-9001-102 study, and ... https://www.cgtlive.com Sarepta Therapeutics Announces U.S. FDA Acceptance of an ...
ELEVIDYS has been evaluated in four clinical studies: SRP-9001-101, SRP-9001-102, SRP-9001-103 (ENDEAVOR) and SRP-9001-301 (EMBARK). Accelerated approval of ... https://investorrelations.sare 《生技投資》Sarepta 之前表示治療杜氏肌肉萎縮症SRP-9001 ...
2023年3月20日 — 不過事實是,FDA 宣布將在5 月29 日決定藥症是否給予的日期之前召開SRP-9001研究基因治療諮詢委員會會議。這代表有沒有安全問題,還沒有一個定數,這也 ... http://www.genetinfo.com Voluntary Consensus Standards Recognition Program for ...
2023年11月27日 — This guidance describes a standards recognition program for regenerative medicine therapies (SRP-RMT) at FDA's Center for Biologics ... https://www.fda.gov |